Respirion Pharmaceuticals
Perth
About Respirion Pharmaceuticals
Founded in 2018, Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory disease. The Company is a spinout from the Telethon Kids Institute in Perth where the product development was incubated. Respirion’s lead product, an inhaled therapy for the life-threatening disease Cystic Fibrosis, has shown promising results in an early clinical study carried out with the Western Australian Department of Health. The Company has partnered with Australia’s largest life science investment fund, the Medical Research Commercialisation Fund, and the US Cystic Fibrosis Foundation to conduct further clinical trials in Australia and the US.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $14.8M
- Last round: Grant (Nov 2025)
- Website: respirionpharma.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Diagnostics, Pharmaceutical
Canonical: https://fsome.com/organization/respirion-pharmaceuticals-128729 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.